- A new strategy for the development of highly potent and selective plasmin inhibitors
-
A new structure-based strategy for the design of potent and selective plasmin inhibitors was developed. These compounds could be prepared by cyclizations between the P3 and P2 amino acid residues of substrate-analogue inhibitors using metathesis or a copper-catalyzed azide alkyne cycloaddition in combination with standard peptide couplings. The most potent bis-triazole derivative 10 inhibits plasmin and plasma kallikrein with Ki of 0.77 and 2.4 nM, respectively, whereas it has poor activity against the related trypsin-like serine proteases thrombin, factor Xa, or activated protein C. Modeling experiments revealed that inhibitor 10 adopts a compact and rigid structure that fits well into the relatively open active site of plasmin and plasma kallikrein, while it is rejected from sterically demanding residues present in loops of the other enzymes. These results from modeling confirm the selectivity profile found for inhibitor 10 in enzyme kinetic studies. Such compounds might be useful lead structures for the development of new antifibrinolytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to reduce bleeding complications.
- Saupe, Sebastian M.,Steinmetzer, Torsten
-
supporting information; experimental part
p. 1171 - 1180
(2012/04/17)
-
- SERINE PROTEASE INHIBITORS
-
The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the prevention of blood loss, and as components of fibrin adhesives.
- -
-
Page/Page column 41
(2012/02/01)
-
- N-sulphonylated amino acid derivatives, method for the production and use thereof
-
The present invention relates to N-sulfonylated amino acid derivatives, where an aryl radical is linked via the sulfonyl group N-terminally to the amino acid and a radical which comprises at least one imino group and at least one further basic group which
- -
-
-
- METHOD FOR CLEANING 3-HYDROXYAMIDINOPHENYLALANINE DERIVATIVES BY THE PRECIPITATION AND RECRYSTALLISATION OF A SALT AND AN AROMATIC SULPHONIC ACID
-
The invention relates to a method for cleaning 3-hydroxyamidinophenylalanine derivatives comprising the steps: (a) addition of an aromatic sulphonic acid to a solution of an optionally contaminated 3-hydroxyamidinophenylalanine derivative in order to form a precipitate; (b) separation of the precipitate formed in step (a); and (c) recovery of the free 3-hydroxyamidinophenylalanine derivative from the precipitate. 3-hydroxyamidinophenylalanine derivatives can e.g. be used as urokinase inhibitors. The invention also relates to the use of highly pure 3-hydroxyamidinophenylalanine derivatives for producing 3-amidinophenylalanine derivatives.
- -
-
Page/Page column 12
(2008/06/13)
-
- N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
-
The invention relates to N-sulphonylated amino acid derivatives wherein an aryl radical is bound to an amino acid via the sulphonyl groups in the N-terminal and a radical is bound in the C-terminal via the carbonyl group. Said radical contains at least one imino group and at least one other basic group representing an optionally modified amino-, amidino- or guanidino group. The invention also relates to a method for the production of said compounds and to the use thereof, especially as inhibitors of matriptase.
- -
-
Page/Page column 51
(2010/02/09)
-
- Arginine mimetics as factor Xa inhibitors
-
The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor Xa; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic therapy.
- -
-
-
- PIPERAZIDES OF SUBSTITUTED PHENYLALANINE DERIVATIVES AS THROMBIN INHIBITORS
-
The present invention relates to D,L-, L-and D-phenylalanine piperazides of formula (I) defined in claim 1 that inhibit blood coagulation, and thrombin and/or trypsin, respectively. The compounds are extraordinarily absorbable after oral, intraduodenal an
- -
-
-